These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33210958)

  • 21. Marine compounds with therapeutic potential in gram-negative sepsis.
    Solov'eva T; Davydova V; Krasikova I; Yermak I
    Mar Drugs; 2013 Jun; 11(6):2216-29. PubMed ID: 23783404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.
    Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Orlando F; Silvestri C; Bozzi A; Di Giulio A; Luzi C; Mangoni ML; Barra D; Saba V; Scalise G; Rinaldi AC
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2478-86. PubMed ID: 16801429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of efflux pump inhibitors to treat Gram-negative infections.
    Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
    Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
    Domalaon R; Idowu T; Zhanel GG; Schweizer F
    Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29540434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.
    Dofferhoff AS; Nijland JH; de Vries-Hospers HG; Mulder PO; Weits J; Bom VJ
    Scand J Infect Dis; 1991; 23(6):745-54. PubMed ID: 1815338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep19-2.5.
    Heinbockel L; Weindl G; Martinez-de-Tejada G; Correa W; Sanchez-Gomez S; Bárcena-Varela S; Goldmann T; Garidel P; Gutsmann T; Brandenburg K
    Front Immunol; 2018; 9():1704. PubMed ID: 30093904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics.
    Wong KF; Luk JM
    Protein Pept Lett; 2009; 16(5):539-42. PubMed ID: 19442233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.
    Monogue ML; Kuti JL; Nicolau DP
    Expert Rev Clin Pharmacol; 2016; 9(3):459-76. PubMed ID: 26678036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of antibiotic-induced endotoxin release in septic shock.
    Lepper PM; Held TK; Schneider EM; Bölke E; Gerlach H; Trautmann M
    Intensive Care Med; 2002 Jul; 28(7):824-33. PubMed ID: 12122518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Host Defense Proteins and Peptides with Lipopolysaccharide-Binding Activity from Marine Invertebrates and Their Therapeutic Potential in Gram-Negative Sepsis.
    Solov'eva TF; Bakholdina SI; Naberezhnykh GA
    Mar Drugs; 2023 Nov; 21(11):. PubMed ID: 37999405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.
    Brandenburg K; Ferrer-Espada R; Martinez-de-Tejada G; Nehls C; Fukuoka S; Mauss K; Weindl G; Garidel P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria.
    Liu Y; Li R; Xiao X; Wang Z
    Crit Rev Microbiol; 2019 May; 45(3):301-314. PubMed ID: 30985240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.
    Huwaitat R; McCloskey AP; Gilmore BF; Laverty G
    Future Microbiol; 2016 Jul; 11():955-72. PubMed ID: 27357521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advances in the development of neutralizing therapies for sepsis].
    Florencia Henning M; Garda H; Bakás L
    Medicina (B Aires); 2006; 66(3):263-73. PubMed ID: 16871917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic-induced release of endotoxin: a reappraisal.
    Hurley JC
    Clin Infect Dis; 1992 Nov; 15(5):840-54. PubMed ID: 1445982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.